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Hypertension is a major risk factor for cardiovascular and cerebrovascular diseases. The risk of both increases with 
blood pressure, even within the normal range.1 Blood pressure 
has a substantial heritable component, and although polymor-
phic variations in a small number of genes have been shown 
to associate with blood pressure levels, much of this genetic 
component remains unidentified. Recently, the International 
Consortium for Blood Pressure genome-wide association study 
(GWAS), using 200 000 individuals of European descent, identi-
fied 16 novel loci as being significantly associated with systolic 
blood pressure or diastolic blood pressure2 and also confirmed 
the association at 12 loci reported by the Cohorts for Heart and 
Aging Research in Genetic Epidemiology (CHARGE)3 and 
Global Blood Pressure Genetics (Global BPgen)4 consortia. 
Abstract—Genome-wide association studies implicate the CYP17A1 gene in human blood pressure regulation although 
the causative polymorphisms are as yet unknown. We sought to identify common polymorphisms likely to explain this 
association. We sequenced the CYP17A1 locus in 60 normotensive individuals and observed 24 previously identified 
single-nucleotide polymorphisms with minor allele frequency >0.05. From these, we selected, for further studies, 7 
polymorphisms located ≤2 kb upstream of the CYP17A1 transcription start site. In vitro reporter gene assays identified 
3 of these (rs138009835, rs2150927, and rs2486758) as having significant functional effects. We then analyzed the 
association between the 7 polymorphisms and the urinary steroid metabolites in a hypertensive cohort (n=232). Significant 
associations included that of rs138009835 with aldosterone metabolite excretion; rs2150927 associated with the ratio of 
tetrahydrodeoxycorticosterone to tetrahydrodeoxycortisol, which we used as an index of 17α-hydroxylation. Linkage 
analysis showed rs138009835 to be the only 1 of the 7 polymorphisms in strong linkage disequilibrium with the blood 
pressure–associated polymorphisms identified in the previous studies. In conclusion, we have identified, characterized, 
and investigated common polymorphisms at the CYP17A1 locus that have functional effects on gene transcription in 
vitro and associate with corticosteroid phenotype in vivo. Of these, rs138009835—which we associate with changes in 
aldosterone level—is in strong linkage disequilibrium with polymorphisms linked by genome-wide association studies 
to blood pressure regulation. This finding clearly has implications for the development of high blood pressure in a 
large proportion of the population and justifies further investigation of rs138009835 and its effects.  (Hypertension. 
2016;67:724-732. DOI: 10.1161/HYPERTENSIONAHA.115.06925.) • Online Data Supplement
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Of these 28 loci, 1 on chromosome 10 encompasses a cluster 
of 5 genes forming a high linkage disequilibrium (LD) block 
spanning 347 kb.5 This locus was flagged by all 3 GWASs; the 
most associated variant was rs1004467, located in intron 3 of 
CYP17A1 in the CHARGE study, whereas the most associated 
variant in the other 2 studies was rs11191548, which lies some 
250 kb distant from CYP17A1 at the intergenic region between 
CNNM2 and NT5C2 and is in high LD with rs1004467 (r2=0.91 
in the 1000 Genomes CEU population of Utah residents with 
Northern and Western European ancestry). In each of the stud-
ies, this locus was associated with a potential difference in sys-
tolic blood pressure of ≈1.1 mm Hg. Subsequent replication of 
the GWAS findings in East Asian populations has increased the 
potential global effect of the CYP17A1 locus.6–9 A recent study 
has also associated rs11191548 with left ventricular mass 
index in hypertensive patients, which is suggestive of a role in 
cardiac hypertrophy.10 Rare genetic variants at CYP17A1 are 
already known to cause hypertension, and so, this locus rep-
resents a rare concurrence of blood pressure candidate gene 
studies with GWAS evidence.
The CYP17A1 gene is located on chromosome 10q24 and 
encodes a dual-function cytochrome P450 enzyme expressed 
primarily in the adrenal cortex, ovarian thecal cells, and testes. In 
the adrenal zona fasciculata, this CYP17A1 enzyme functions as 
a 17α-hydroxylase, converting pregnenolone and progesterone 
to 17α-hydroxypregnenolone and 17α-hydroxyprogesterone, 
respectively.11 In the zona reticularis, it acts as a 17,20-lyase 
on these hydroxylated products, cleaving the C17,20 bond to 
produce dehydroepiandrosterone and androstenedione. The 
cofactor cytochrome b5 is an important determinant of the bal-
ance between these 2 enzymatic functions.12 Recently, the sub-
stantial heritability of 17α-hydroxylase activity in the general 
population has been demonstrated as has its inverse correla-
tion with adult blood pressure.13 Deficient 17α-hydroxylation 
has been known for almost 50 years to result in hypertension, 
with mutation of the CYP17A1 gene now estimated to account 
for ≈1% of congenital adrenal hyperplasia cases.14,15 Causative 
mutations usually occur in exons or at intronic splice sites, 
resulting in defective androgen production—which disrupts 
sexual development and maturation—and a markedly reduced 
ability to synthesize cortisol. The consequent sustained surge 
in adrenocorticotropic hormone production stimulates high 
secretion of the weak mineralocorticoid, 11-deoxycorticoste-
rone (DOC), causing hypertension, hypokalemia, and suppres-
sion of aldosterone synthesis. Simultaneously, high levels of 
corticosterone compensate for cortisol deficiency. A valuable 
biochemical indicator is, therefore, an abnormal excess of 
17-deoxycorticosteroids (ie, DOC and corticosterone) and low-
ered 17α-hydroxycorticosteroids (eg, 17-OH-pregenenolone 
and 17-OH-progesterone).
We hypothesized that common CYP17A1 polymorphisms 
exist, which influence the blood pressure and account for the 
significant association identified at this locus. In this study, 
therefore, we took the crucial next step of identifying common 
polymorphic variations within CYP17A1 and investigating 
their potential effects on biochemical function. We first char-
acterized the polymorphic frequency and distribution in nor-
motensive individuals and investigated the effects of selected 
polymorphisms on gene transcription in vitro. We then tested 
for the association between these candidate polymorphisms 
and intermediate corticosteroid phenotype in a large hyper-
tensive cohort. As a result, we demonstrate that common 
CYP17A1 polymorphisms significantly alter gene function 
and correlate with changes in intermediate corticosteroid phe-
notype—including a significant effect on aldosterone levels—
that could account for the strong association of this locus with 
population blood pressure variation.
Methods
Polymorphism Discovery in Normotensive Subjects
Genetic polymorphisms at the CYP17A1 locus were identified by 
direct sequencing of genomic DNA from 60 West of Scotland vol-
unteers (27 men and 33 women) recruited for a previous study.16 
Participants were in good health and taking no antihypertensive 
medication. Median age was 51 years (interquartile range, 32–67 
years); median weight was 70 kg (interquartile range, 61–76 kg); 
median systolic blood pressure was 126 mm Hg (interquartile range, 
116–136 mm Hg); median diastolic blood pressure was 77 mm Hg 
(interquartile range, 70–84 mm Hg). Ethical approval was granted 
by the West Glasgow Ethics Committee, and written informed con-
sent was obtained from all participants. Exons, introns, and 3′UTR 
were each amplified separately by polymerase chain reaction (PCR) 
using the Thermo-Start Taq DNA Polymerase PCR Enzyme Kit 
(Thermo Fisher Scientific, Renfrew, United Kingdom), whereas the 
upstream region was amplified using the Expand High Fidelity PCR 
System (Roche Diagnostics Ltd, Burgess Hill, United Kingdom), 
each according to the standard kit protocol. Automated sequencing 
of PCR products was performed using BigDye Terminator version 
3.1 Cycle Sequencing chemistry (Life Technologies, Renfrew, United 
Kingdom) and the ABI 3730 DNA analyzer (Life Technologies). 
Further details are available in Tables S2 and S3 in the online-only 
Data Supplement. Investigations were carried out in accordance with 
the principles of the Declaration of Helsinki. LD patterns were gener-
ated using Haploview software.17
Site-Directed Mutagenesis of CYP17A1 Luciferase 
Reporter Vector
To create the pGL3-17 control vector, 2898bp of human genomic DNA 
immediately upstream of the CYP17A1 coding region was inserted 
into the empty pGL3-basic vector (Promega UK Ltd, Southampton, 
United Kingdom), thereby fusing this sequence to a firefly luciferase 
reporter gene. To investigate the polymorphic effects on CYP17A1 
promoter activity, the pGL3-17 control vector was then mutated 
separately at each of the 7 single-nucleotide polymorphism (SNP) 
positions using the QuikChange Site-Directed Mutagenesis standard 
kit protocol (Agilent Technologies UK Ltd, United Kingdom) and 
specific primers (Eurofins MWG Operon, Ebersberg, Germany; Table 
S4). The resulting 7 vectors were each used to transform JM109 com-
petent cells (100 µL; Promega, United States) by heat shock and puri-
fied using the QIAprep Spin Miniprep kit (QIAGEN, Crawley, United 
Kingdom). Direct sequencing of the entire insert and flanking regions 
confirmed the correct incorporation of the desired polymorphism 
in each of the 7 plasmids and the absence of additional unintended 
mutations.
Luciferase Reporter Gene Assays
H295R cells (a kind gift from Professor William E. Rainey, University 
of Michigan) were grown in DMEM/F12 medium supplemented with 
2.5% Ultroser G serum (Pall Bioscience, Saint-Germain-en-Laye, 
France), 1% insulin–transferrin–selenium (BD Biosciences, Oxford, 
United Kingdom), and 1% penicillin–streptomycin (1 IU penicillin 
and 100 µg/mL streptomycin; Life Technologies) at 37°C, 5% CO2, 
and transfected with the pGL3-17 control vector or 1 of its 7 mutated 
derivative vectors using siPORT NeoFX transfection agent (Life 
Technologies) according to the manufacturer’s protocol at a final 
cell density of 8×104 cells per well. A pGL4.73 (renilla luciferase; 
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Promega) construct was cotransfected at a ratio of 50:1 to control 
for transfection efficiency. After 24 hours, transfectant was removed 
and replaced with complete medium or complete medium contain-
ing 1 mmol/L dibutyryl cAMP for 24 hours. The Dual Luciferase 
Reporter Assay system (Promega) was used to measure firefly and 
renilla luciferase activity in cell lysates containing 1× passive lysis 
buffer, according to the manufacturer’s instructions, on a Lumat LB 
9507 tube luminometer (Berthold Technologies, United Kingdom).
Genotype/Phenotype Associations in the 
Hypertensive British Genetics of Hypertension 
Cohort
The Medical Research Council British Genetics of Hypertension 
(BRIGHT) cohort is a large multicentre study, with white and British 
ancestry confirmed to the grand-parental level for all participants. Data 
presented here are related to 232 unrelated and successfully genotyped 
hypertensive individuals drawn randomly from the BRIGHT sibling-
pair group (Table 1) for whom 24-hour urinary corticosteroid metabo-
lite measurements, previously generated by gas chromatography/mass 
spectrometry,18 were available. Recruitment to the study required blood 
pressure values of 150/100 mm Hg or higher, based on 1 reading, or 
145/90 mm Hg, as a mean of 3 readings, with onset of hypertension 
diagnosed before the age 60 years in at least 1 sibling; subjects with 
body mass index >30 were excluded.19 Ethical approval for this study 
was granted by the local ethics committees of the participating centers, 
and fully informed written consent of the subjects was obtained. The 
2.4-kb upstream region was amplified using the Expand High Fidelity 
PCR System (Roche Diagnostics Ltd), according to the standard kit 
protocol. Automated sequencing of PCR products was performed using 
BigDye Terminator version 3.1 Cycle Sequencing chemistry (Life 
Technologies) and the ABI 3730 DNA analyzer (Life Technologies). 
Further details are available in Table S5. Measurement of urinary cor-
ticosteroid metabolites by gas chromatography/mass spectrometry 
was conducted as previously described.18,20
Statistics
In vitro experiments were performed in quadruplicate on 4 indepen-
dent occasions (analyzed as n=4), with data presented as the mean 
and SEM. The activity of pGL3-basic and pGL3-17 control constructs 
(Figure 2A) was compared using 1-way ANOVA and Bonferroni 
post hoc tests on log-transformed values; mutated luciferase vector 
activity (Figure 2B and 2C) was analyzed by 1-sample Student t test 
on log-transformed values. For analysis of the BRIGHT subjects, 
demographic and steroid excretion data were not normally distributed 
and were, therefore, analyzed by the nonparametric Mann–Whitney U 
test. Comparisons of genotype with steroid excretion were conducted 
using the dominant model where heterozygote and minor allele homo-
zygote data are grouped and compared against major allele homozy-
gote data. In all instances, 95% confidence intervals were generated 
and a P value of <0.05 was set as the threshold for significance.
Results
Polymorphism Distribution Across the CYP17A1 
Locus
The entire CYP17A1 locus, including exons, introns, and 
a 2-kb region upstream of the transcription start site (TSS), 
was sequenced using genomic DNA sourced from 60 healthy 
white volunteers, identifying 36 polymorphisms with minor 
allele frequencies ranging from 0.008 to 0.322 (Table S1). All 
polymorphisms within the coding region were synonymous, 
and none was observed at intronic splice sites. Pairwise LD 
was analyzed between the 24 most common polymorphisms 
(all minor allele frequencies, >0.05) using Haploview soft-
ware (Figure 1A). We focused on 7 common polymorphisms 
located upstream of the CYP17A1 coding region with the 
potential to influence gene transcription (Figure 1B). Analysis 
of pairwise LD between these SNPs has identified 2 dis-
tinct polymorphic blocks in this area, which we termed LD 
blocks 1 and 2. LD block 1 is comprised of 6 of the 7 SNPs, 
which display a high degree of pairwise LD with one another 
(Figure 1C). LD block 2 includes the remaining seventh SNP, 
rs138009835, which is less strongly linked to the other 6 but 
is in high LD with 3 further variants that span the CYP17A1 
locus and include rs1004467, the intron 3 SNP associated with 
blood pressure in the CHARGE GWAS (Figure 1D).3
Effect of Common Polymorphisms on CYP17A1 
Transcription
The effect of the 7 upstream polymorphisms on CYP17A1 
gene transcription was assessed in vitro through transfection 
Table 1. Demographic and Urinary Corticosteroid Data (Median and Interquartile Ranges) for the British 
Genetics of Hypertension Study Subgroup
Urinary Steroid Metabolite  
(µg per 24 h) All Subjects (n=232) Men (n=106) Women (n=126) P Value (Men vs Women)
Age, y 63 (56–69) 63 (56–68) 64 (56–69) 0.47
SBP, mm Hg 157 (153–190) 157 (151.25–187) 181.5 (153–191) 0.07
DBP, mm Hg 103 (98–110) 103 (98–110) 102 (98–109.5) 0.43
BMI, kg/m2 27 (25–30) 28 (25–30.75) 27 (25–30) 0.26
WHR 0.88 (0.81–0.93) 0.93 (0.90–0.97) 0.82 (0.78–0.86) <0.001
Corticosterone (Total B: 
THB+aTHB+THA)
103 (61–188) 140 (79–228) 86.5 (54–156) <0.001
Cortisol (Total F: THF+aTHF+THE) 1467 (759–2559) 2081 (1130–3526) 1118 (661–1989) <0.001
Androgens (DHEA+Aetio+Andro) 613 (322–1227) 1008 (503–1852) 447 (225–815) <0.001
Aldosterone (THAldo) 3 (1–5) 3 (2–6) 2 (1–4) 0.002
Men and women were compared by the nonparametric Mann–Whitney U test. Aetio indicates aetiocholanolone; Andro, androsterone; 
aTHB, allotetrahydrocorticosterone; aTHF, allotetrahydrocortisol; BMI, body mass index; DBP, diastolic blood pressure; DHEA: 
dehydroepiandrosterone; SBP, systolic blood pressure; THA, tetrahydro-11-dehydrocorticosterone; THAldo, tetrahydroaldosterone; 
THB, tetrahydrocorticosterone; THE, tetrahydrocortisone; THF, tetrahydrocortisol; and WHR: waist:hip ratio.
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of the H295R adrenocortical cell line with reporter con-
structs containing 2.9 kb of the CYP17A1 5′ upstream 
region fused to a firefly luciferase reporter gene. Reporter 
gene activity was measured under basal conditions and 
after 24-hour stimulation with dibutyryl cAMP to mimic 
the intracellular activation of cAMP by adrenocorticotropic 
hormone. Dibutyryl cAMP caused a 2- to 3-fold increase in 
the activity of the pGL3-17 control vector relative to basal 
(Figure 2A). Site-directed mutagenesis of this vector gen-
erated 7 further plasmids, each varying from the control 
sequence only at a single polymorphic base. Under basal 
conditions, 3 polymorphisms resulted in differential tran-
scriptional activity: the minor C allele at position −362 
(rs2486758) significantly increased transcriptional activity 
relative to the control T allele, whereas the minor A allele 
at position −1877 (rs138009835) and the major G allele at 
position −2205 (rs2150927) each reduced the activity rela-
tive to their control forms (Figure 2B). The polymorphisms 
at the other 4 sites had no significant effect on transcription.
Incubation of H295R cells with dibutyryl cAMP stimu-
lated the transcription of all constructs relative to basal con-
ditions. The same 3 polymorphisms resulted in significantly 
different transcriptional activity under these stimulated condi-
tions as they had under basal conditions (Figure 2C). Although 
the magnitude of change relative to the control vector was 
similar under basal and stimulated conditions for the −362 
Figure 1. Pairwise linkage disequilibrium (LD) plots, generated using default settings in Haploview software, showing common 
polymorphisms (minor allele frequency, >0.05) at the CYP17A1 locus in a cohort of 60 normotensive volunteers. The various LD plots 
show variants found across the entire human CYP17A1 locus (A), the 7 variants subjected to subsequent detailed analysis in vitro and in 
the British Genetics of Hypertension (BRIGHT) study (B), the 6 highly linked variants comprising LD block 1 (C), and the 4 highly linked 
variants comprising LD block 2 (D). D′ values (%) are displayed for each pair of single-nucleotide polymorphisms in the intersecting 
square; squares not displaying a figure are D′=100%. Red squares indicate high D′ and a logarithm of the odds (LOD) score of ≥2; blue 
squares indicate high D′ and an LOD score of <2; white squares indicate low D′ (≤80%) and an LOD score of ≥2.
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(rs2486758) and −1877 (rs138009835) vectors, the differ-
ences between the alternative forms of the −2205 (rs2150927) 
vector were more pronounced under stimulation.
Association of CYP17A1 Polymorphisms With 
Steroid Phenotype in a Hypertensive Population
A subset of 232 hypertensive BRIGHT study subjects (106 
men and 126 women) for whom urinary corticosteroid excre-
tion data were available20 was genotyped for the 7 polymor-
phisms. Age, systolic blood pressure, diastolic blood pressure, 
and body mass index did not vary significantly with genotype 
(Table S5) or with sex (Table 1) although levels of tetrahy-
droaldosterone, total corticosterone metabolites (Total B), total 
cortisol metabolites (Total F), and total androgen metabolites 
were all significantly lower in women (all P<0.01; Table 1).
To provide sufficient power to identify significant asso-
ciations between corticosteroid biosynthesis and CYP17A1 
genotype, data were analyzed using a dominant model, group-
ing heterozygotes with minor allele homozygotes for com-
parison against major allele homozygotes (Table 2). None 
of the 7 SNPs departed significantly from Hardy–Weinberg 
equilibrium, and stratification of the study subjects by geno-
type revealed no association with key demographic charac-
teristics, including blood pressure and body mass index (data 
not shown). All significant associations identified between the 
SNP genotype and the steroid phenotype are detailed below.
Although none of the 7 SNPs associated with significant 
differences in Total B, total androgen metabolites, or Total 
F, when the study population were analyzed as a whole, 
women homozygous for the major alleles at rs10786713 and 
at rs2150927 (A and G, respectively) had significantly lower 
levels of Total F metabolites (each P<0.05) when analyzed 
separately as did men homozygous for the major T allele at 
rs2486758 (P<0.05 relative to heterozygotes only; the cohort 
contained no men homozygous for the minor allele at this 
locus; Figure 3).
The ratios of tetrahydrodeoxycorticosterone to tetrahy-
drodeoxycortisol (THDOC:THS) and Total B:Total F serve 
as indices of 17α-hydroxylase activity. Subjects homozygous 
for the major alleles of rs743572, rs10786713, and rs2150927 
all associated with a significantly higher THDOC:THS ratio 
(each P<0.05), suggesting less efficient 17α-hydroxylation 
(Figure 4). For each of these SNPs, this effect was more pro-
nounced in women than in the total population (each P<0.01) 
and was not significant in men alone, when analyzed sepa-
rately (all P>0.05). Female subjects homozygous for the major 
forms of 2 of these SNPs—rs10786713 A and rs2150927 
G—had a higher Total B:Total F ratio (P<0.05), again indi-
cating less efficient hydroxylation; no such difference was 
detectable in men alone or in the total cohort (Figure 5).
Ratios of THS:dehydroepiandrosterone and Total F:total 
androgen metabolites, selected as indices of 17,20 lyase activ-
ity, showed no significant association with any of the 7 SNPs 
(data not shown).
Major allele homozygotes for rs138009835 (GG geno-
type) had significantly higher levels of the urinary aldosterone 
metabolite tetrahydroaldosterone (P<0.05) in comparison with 
combined heterozygote and minor allele subjects (Figure 6). 
In separate analyses of men and women, there was no signifi-
cant difference in tetrahydroaldosterone between these allele 
groups (P=0.14 and P=0.34, respectively).
Discussion
Our systematic sequencing of a normotensive population 
identified 24 common (minor allele frequency, >0.05) poly-
morphisms spanning the CYP17A1 locus. None is located 
within the coding region of CYP17A1 or at positions liable to 
disrupt mRNA splicing. Seven common SNPs located ≤2.2 kb 
from the TSS form 2 distinct and independent linkage blocks. 
Three of these SNPs disrupt in vitro CYP17A1 transcription: 
Figure 2. A, H295R cells were transfected with pGL3-basic or 
pGL3-17 control reporter constructs and grown for 24 hours post 
transfection under basal or 1 mmol/L dibutyryl cAMP–stimulated 
conditions. The transcriptional activity of each reporter construct 
is displayed as a proportion of pGL3-basic (empty vector) 
activity (normalized to 1). B and C, H295R cells were transfected 
with reporter constructs varying in sequence from the pGL3-
17 control vector (CTRL) at a single base and then grown for 
24 hours post transfection under either basal (B) or 1 mmol/L 
dibutyryl cAMP–stimulated (C) conditions. The transcriptional 
activity of each reporter construct and of a pGL3-basic empty 
construct (E) is displayed as a proportion of pGL3-control activity 
(normalized to 1). D, Table of reporter construct genotypes; major 
alleles are indicated by a superscript M. Vector alleles match 
the control unless otherwise indicated. All data are expressed 
as the mean (±SEM) of 4 independent experiments (n=4), each 
performed in quadruplicate.
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2 from LD block 1 (rs2486758 and rs2150927) and 1 from 
LD block 2 (rs138009835). Previous reporter construct stud-
ies found that the 227 bp lying immediately upstream of the 
human CYP17A1 TSS account for ≈60% to 80% of basal 
transcriptional activity at that locus21; none of our 7 common 
SNPs lies in that area (rs743572 lies between the TSS and 
the start codon of CYP17A1). Therefore, a great deal of the 
basal—not to mention cAMP activated—transcriptional activ-
ity can be attributed to the region further upstream where 6 
of the common SNPs are found. Our own previous studies 
show that transcriptional activity of steroidogenic genes can 
be significantly altered by functional polymorphisms lying 
some 1500 to 2000 bases upstream of the TSS, which alter 
transcription factor–binding affinity.16,18 We propose that the 
blood pressure association identified by GWAS at this locus 
is, therefore, most likely to result from ≥1 of the common 
SNPs that significantly alter in vitro transcription: rs2486758, 
rs138009835, and rs2150927.
Our analysis associates the major forms of the 2 func-
tional polymorphisms found in LD block 1, rs2486758 and 
rs2150927, with sex-dependent changes in the corticosteroid 
excretion rate profiles in hypertensive individuals. (The LD 
block 1 SNP, rs10786713, also shows the same association 
although this had no functional effect in vitro.) These changes 
in the phenotype are consistent with altered 17α-hydroxylase 
efficiency; the similarity of these effects together with the 
close linkage of these SNPs suggests a common underlying 
factor. There is no associated effect on the aldosterone excre-
tion rate. Conversely, the sole transcriptionally functional LD 
block 2 SNP, rs138009835, shows no association with appar-
ent 17α-hydroxylase efficiency but is significantly associated 
with changes in the aldosterone excretion rate. The influence 
of the LD block 1 polymorphisms on steroid profile is con-
sistent with their effects on CYP17A1 transcription in vitro: 
the major alleles rs2486758 T and rs2150927 G each reduce 
transcription relative to their alternative forms and associ-
ate with less efficient hydroxylation in vivo, as reflected in 
lower Total F for both SNPs and higher Total B:Total F and 
THDOC:THS ratios for rs2150927. The rs10786713 A allele 
has similar associations in vivo but no significant effect on 
transcription, implying that its association with the steroid 
profile is the result of linkage to one or the other of the func-
tional block 1 polymorphisms. On the basis of the observed 
steroid ratios, 17-lyase efficiency is unaffected by any of the 
7 analyzed SNPs.
The altered 17α-hydroxycorticosteroid:17-deoxycorticos-
teroid ratios in subjects carrying the major alleles at selected 
SNPs imply that they will have higher adrenocorticotropic 
Table 2.  Genotype Data for Selected SNPs Upstream of CYP17A1
SNP ID CYP17A1 Location
Chromosomal 
Location Alleles
Minor Allele 
Frequency HWE (P Value) % Genotyped
rs743572 1 −34 10:104597152 A/G 0.420 0.9276 96.9
rs2486758 2 −362 10:104597480 T/C 0.183 0.9940 96.9
rs10883784 3 −804 10:104597922 C/T 0.304 0.7485 100.0
rs10786713 4 −1204 10:104598322 A/G 0.417 0.9121 99.6
rs10786714 5 −1488 10:104598606 G/C 0.304 0.6991 99.6
rs138009835 6 −1877 10:104598995 G/A 0.109 1.0000 100.0
rs2150927 7 −2205 10:104599323 G/A 0.413 0.9276 99.1
Genotypes were generated from a subset (n=232) of the hypertensive British Genetics of Hypertension (BRIGHT) population. Major alleles are 
listed first, and the given bases are from the forward strand sequence. The CYP17A1 location is relative to the first codon. HWE indicates Hardy–
Weinberg equilibrium; and SNP, single-nucleotide polymorphism.
Figure 3. Box–whisker plots of 24-hour total cortisol metabolites (Total F) in the British Genetics of Hypertension (BRIGHT) study 
subgroup (n=232), stratified by rs10786713 genotype (B), rs2150927 genotype (B), and rs2486758 genotype (C). Total F is the sum of 
tetrahydrocortisol, allotetrahydrocortisol, and tetrahydrocortisone. Plots show the median within the interquartile range box, with whiskers 
extending to the fifth and 95th percentiles; data points beyond the whiskers are displayed as dots. Groups were compared by Mann–
Whitney nonparametric test; *P<0.05.
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hormone drives to maintain normal cortisol levels. There is 
a clear sex difference in the steroid effects of block 1 poly-
morphisms, with women tending to have the more altered 
intermediate phenotype. This may be related to the fact that 
the women in this cohort have a tendency to higher blood 
pressure relative to men although this does not achieve 
significance (P=0.07; Table 1). Nevertheless, if impaired 
17α-hydroxylase function results in increased blood pressure, 
it seems legitimate to conclude that such an effect is due—
at least in part—to sustained changes in the adrenal steroid 
profile. In classical 17α-hydroxylase deficiency, massive 
DOC excess causes an easily recognizable mineralocorticoid 
hypertension. Whether the small differences in the proportion 
of DOC in our population—even persisting over the course of 
a lifetime—could account for the small but significant blood 
pressure effects identified by GWAS is debatable although the 
potency of DOC relative to aldosterone remains the subject 
of discussion.22 Alternatively, corticosterone could be respon-
sible. In our study group, women carrying the major alleles at 
rs10786713 and rs2150927 had higher corticosterone:cortisol 
ratios. Previously, Soro et al23 found levels of corticosterone to 
be higher in subjects with hypertension. This may be related 
to the easier access corticosterone has to the brain when com-
pared with cortisol24; its concentration relative to cortisol in 
cerebrospinal fluid is much higher than in plasma,25 and it may 
be preferentially retained in specific regions of the brain,26 
where it occupies both mineralocorticoid and glucocorticoid 
receptors. Recently, Morris27 has argued that corticosterone is 
not merely a minor glucocorticoid subsidiary to cortisol but 
has distinct properties (eg, higher mineralocorticoid activity 
and lower susceptibility to 11β-hydroxysteroid dehydroge-
nase types 1 and 2) that might cause it and its 5α-metabolites 
to affect blood pressure significantly.
Of the 7 analyzed SNPs, only rs138009835 is found in LD 
block 2 and is, therefore, strongly linked to the blood pres-
sure GWAS variants at this locus. It shows no association with 
our chosen indices of steroid 17α-hydroxylation efficiency in 
vivo, but its major G allele—which causes increased CYP17A1 
transcription in vitro—does associate with higher levels of 
aldosterone in a nonsex-dependent manner, unrelated to the 
effects of the LD block 1 polymorphisms. Given that the zona 
glomerulosa does not express CYP17A1 and has no obvious 
direct interaction with the zona fasciculata, the influence of 
this SNP on aldosterone levels is not open to a simple expla-
nation. Regardless of the precise mechanism, we demonstrate 
here that the rs138009835 G allele associates with increased 
CYP17A1 transcription in vitro and with raised aldosterone 
levels in vivo. Given its strong linkage (via LD block 2) to 
the A allele of rs1004467—itself significantly associated with 
increased blood pressure—and the critical role of aldosterone 
Figure 4. Box–whisker plots of 24-hour tetrahydrodeoxycorticosterone to tetrahydrodeoxycortisol (THDOC:THS) ratio in the British 
Genetics of Hypertension (BRIGHT) study subgroup (n=232), stratified by rs743572 genotype (A), rs10786713 genotype (B), and 
rs2150927 genotype (C). Plots show the median within the interquartile range box, with whiskers extending to the fifth and 95th 
percentiles; data points beyond the whiskers are displayed as dots. Groups were compared by Mann–Whitney nonparametric test; 
*P<0.05 and **P<0.01.
Figure 5. Box–whisker plots of 24-hour total 
corticosterone metabolite (Total B) to total 
cortisol metabolite (Total F) ratio in the British 
Genetics of Hypertension (BRIGHT) study 
subgroup (n=232), stratified by rs10786713 
genotype (A) and rs2150927 genotype (B). 
Total B is the sum of tetrahydrocorticosterone, 
allotetrahydrocorticosterone, and tetrahydro-
11-dehydrocorticosterone. Total F is the sum of 
tetrahydrocortisol, allotetrahydrocortisol, and 
tetrahydrocortisone. Plots show the median within 
the interquartile range box, with whiskers extending 
to the 5th and 95th percentiles; data points beyond 
the whiskers are displayed as dots. Groups were 
compared by Mann–Whitney nonparametric test; 
*P<0.05.
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in blood pressure homeostasis, this finding clearly warrants 
further investigation.
This study had limitations and was not designed with the 
intention of detecting direct associations of CYP17A1 genotype 
with blood pressure. Given that the BRIGHT study subjects 
were all hypertensive and on various forms of antihypertensive 
therapy, the lack of association between blood pressure and any 
of the 7 SNPs—including rs138009835—is, therefore, unsur-
prising. It is possible that antihypertensive treatments influ-
enced steroid excretion although previous analysis of the 512 
BRIGHT subjects from which this subset was drawn found 
no evidence that these drugs systematically affected excretion 
rates of cortisol, aldosterone, or androgens.20 Finally, this study 
did not adjust for multiple testing. As such there is a danger 
that some of the results deemed statistically significant may 
be false positives. However, for an exploratory study, such as 
this, it is recognized that adjusting for multiple testing increases 
the chance that real differences will be missed and may not be 
advisable.28 Further investigation in a different study population 
is now recommended to confirm these findings.
Perspectives
Thorough analysis of the CYP17A1 locus in a control human 
population reveals a high degree of genetic variation, including 
2 distinct LD blocks, each containing common upstream SNPs. 
Several of these SNPs significantly affect in vitro gene expres-
sion and associate with in vivo steroid intermediate phenotype 
in a hypertensive population. Although this study was not 
designed with the intention of directly analyzing blood pres-
sure effects, our identification of the functional rs138009835 
SNP might account for the significant blood pressure influence 
at this locus reported by multiple GWAS. The processes by 
which such alterations in CYP17A1 transcriptional regulation 
influence steroid profile and, ultimately, blood pressure require 
further investigation. If subsequent studies confirm CYP17A1 
as a significant factor in population blood pressure variation, it 
has the potential to serve as a prominent target in the treatment 
and control of human hypertension.
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What Is New?
•	Previous genome-wide association studies have linked the CYP17A1 lo-
cus with blood pressure variation.
•	This study presents the first evidence of common functional CYP17A1 
gene polymorphisms. Of these, the transcriptional, phenotypic, and link-
age characteristics of the rs138009835 polymorphism suggest that it 
could underlie the blood pressure associations identified at this locus.
What Is Relevant?
•	Genome-wide association studies have identified several loci as being 
significantly associated with blood pressure. However, few of the mo-
lecular mechanisms underlying these associations have been identified.
•	This study provides functional evidence that could explain the known 
blood pressure associations identified at this region of human chromo-
some 10. The identification of blood pressure–related pathways affected 
by this locus is potentially of high clinical benefit.
•	This study also adds to the substantial evidence base highlighting the 
importance of adrenal steroid biosynthesis in the development of hy-
pertension.
Summary
We report that common genetic polymorphisms at the CYP17A1 
locus alter its expression in vitro and associate with changes in 
steroid levels in vivo. One such variant, rs138009835, is in strong 
linkage disequilibrium with polymorphisms previously identified by 
genome-wide association studies as having significant influence 
on blood pressure. These associations of rs138009835 with tran-
scriptional activity and intermediate steroid phenotype provide a 
plausible mechanism to explain the known blood pressure associa-
tions at this locus.
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Table S1: Genotype data for the 36 polymorphisms identified across the 
CYP17A1 locus in 60 normotensive volunteers. 
SNP: single nucleotide polymorphism; ID: Haploview identification number; Location: 
location of the polymorphism relative to the first CYP17A1 codon; Position: 
chromosomal position from ENSEMBL Homo sapiens version 72.37 (GRCh37); 
Alleles: the major polymorphic form is listed first and the given bases are from the 
forward strand sequence; MAF: minor allele frequency; HWE: Hardy-Weinberg 
equilibrium p-value. * denotes that SNP -638 currently has no allocated rs number. 
 
 
SNP Location Position Alleles MAF HWE (p) 
% 
Genotyped 
rs2150927 -2205 10:104599323 G/A 0.306 0.0973 100 
rs117574307 -1933 10:104599051 G/A 0.032 1.0000 100 
rs138009835 -1877 10:104598995 G/A 0.089 1.0000 100 
rs183906459 -1722 10:104598840 A/T 0.008 1.0000 100 
rs10786714 -1488 10:104598606 G/C 0.210 0.1584 100 
rs544168523 -1366 10:104598484 G/A 0.008 1.0000 100 
rs10786713 -1204 10:104598322 A/G 0.306 0.2835 100 
rs545495641 -1077 10:104598195 G/A 0.008 1.0000 100 
rs10883784 -804 10:104597922 C/T 0.210 0.1584 100 
rs190440742 -734 10:104597852 C/T 0.016 1.0000 100 
-638* -638 10:104597756 G/A 0.016 0.0163 100 
rs61752856 -626 10:104597744 G/A 0.016 1.0000 100 
rs2486758 -362 10:104597480 T/C 0.242 0.9939 100 
rs743572 -34 10:104597152 A/G 0.282 0.0973 100 
rs61754263 Exon 1 10:104597057 C/T 0.008 1.0000 100 
rs6162 Exon 1 10:104596981 G/A 0.315 0.1449 100 
rs6163 Exon 1 10:104596924 C/A 0.306 0.0249 100 
rs10786712 Intron 1 10:104596396 C/T 0.293 0.0232 93.5 
rs45463800 Intron 1 10:104596356 C/T 0.017 1.0000 95.2 
rs754283774 Intron 1 10:104596011 C/T 0.008 1.0000 95.2 
rs3824755 Intron 1 10:104595849 G/C 0.052 1.0000 93.5 
rs284847 Intron 1 10:104595828 G/A 0.068 0.4480 95.2 
rs3781286 Intron 1 10:104595719 C/T 0.302 0.0396 93.5 
rs3781287 Intron 1 10:104595420 T/G 0.322 0.1374 95.2 
rs4919687 Intron 1 10:104595240 G/A 0.241 0.0247 93.5 
rs743575 Intron 2 10:104594906 T/G 0.208 0.4270 96.8 
rs1004467 Intron 3 10:104594507 A/G 0.083 1.0000 96.8 
rs544961235 Intron 4 10:104593194 C/T 0.008 1.0000 95.2 
rs3740397 Intron 5 10:104592675 G/C 0.292 0.1196 96.8 
rs4919686 Intron 6 10:104592249 A/C 0.220 0.0448 95.2 
rs284848 Intron 6 10:104592125 G/A 0.212 1.0000 95.2 
rs45609333 Intron 6 10:104591639 G/A 0.025 1.0000 95.2 
rs17115100 Intron 6 10:104591393 G/T 0.085 1.0000 95.2 
rs284849 Intron 7 10:104591182 G/T 0.234 0.3853 100 
rs10883783 Intron 7 10:104591152 T/A 0.218 0.2194 100 
rs139275291 Intron 7 10:104590871 +/-35bp 0.218 0.2194 100 
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Table S2: Primers used to amplify and sequence CYP17A1 exons in 
normotensive subjects. 
 
Target Exon Primer Type Primer Name Sequence 5’-3’ 
Exon 1 PCR Primers cyp17ex1_f1 CCACTGCTGTCTATCTTGCC 
cyp17ex1_r1 TGAAGACCTGAACAATCCCA 
Sequencing Primers cyp17ex1_f1 CCACTGCTGTCTATCTTGCC 
cyp17ex1_r1 TGAAGACCTGAACAATCCCA 
17Exon1F CAGAGGGTGATCAACTGAC 
17Exon1R CTAGGCATGGTCTGAAGAC 
Exons 2 & 3 
(+ intron 2) 
PCR Primers cyp17ex2+3_f1 GGTGTGAGATTCCTACAGCC 
cyp17ex2+3_r1 TCTACTAGAACCTGAAGGCAG 
Sequencing Primers cyp17ex2+3_f1 GGTGTGAGATTCCTACAGCC 
cyp17ex2+3_r1 TCTACTAGAACCTGAAGGCAG 
cyp17ex2_r1 TCCTAACCCTTACCCCTG 
cyp17ex3_f1 TGGTACAGAGAGGGGGTAAG 
Exon 4 PCR Primers cyp17ex4_f1 GGTGGAGTAGGAACTTCCAG 
cyp17ex4_r2 TCCACCCTGCTCTTGTGATT 
Sequencing Primers cyp17ex4_f1 GGTGGAGTAGGAACTTCCAG 
cyp17ex4_r1 TGTGCCAGGTTCTCTGCTTG 
cyp17ex4_f2 AGCTAAGATCCGCCTCCAG 
cyp17ex4_r2 TCCACCCTGCTCTTGTGATT 
Exons 5 & 6 
(+ intron 5) 
PCR Primers cyp17ex5+6_f1 TGGCAGGAGTGTCACAGATG 
cyp17ex6_r1 TGAATGCATCATGGGGCTAG 
Sequencing Primers cyp17ex5+6_f1 TGGCAGGAGTGTCACAGATG 
cyp17ex5_f1 GGCAGGAGTGTCACAGATG 
cyp17ex5_r1 TGGGGTCTAGGATCAATGAG 
cyp17ex6_f1 ACACACTAGTCACCTCCAAC 
cyp17ex6_r1 TGAATGCATCATGGGGCTAG 
Exons 7 & 8 
(+3’UTR) 
PCR Primers cyp17ex7+8_f1 TTCCTCTTCCACTCTGGAGC 
cyp17ex8utr_r1 GAATGAGTGAGCAAATGAATAC 
Sequencing Primers cyp17ex7+8_f1 TTCCTCTTCCACTCTGGAGC 
cyp17ex8utr_r1 GAATGAGTGAGCAAATGAATAC 
cyp17ex7_r1 TTGGCAGAGGTGAAGGGGTA 
cyp17ex7+8_r1 GCCACATAGGGTGGACAGG 
cyp17ex8_f1 TCAACCAGGGCAGAACCATG 
cyp17ex8_r1 TGTGTTGTGGGGCCACATAG 
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Table S3: Primers used to amplify and sequence CYP17A1 introns in 
normotensive subjects. 
Target 
Intron 
Primer Type Primer Name Sequence 5’-3’ 
Intron 1 PCR Primers intron1F CACCAAGACTACAGTGATTG 
intron1R1 GTGCGCCAGAGTCAGCGAAG 
Sequencing Primers intron1F CACCAAGACTACAGTGATTG 
intron1R1 GTGCGCCAGAGTCAGCGAAG 
intron1s1f CTTAGCCTAGCACCCAGCAC 
intron1s1r AGCTGGAAATAGCACCAGGA 
intron1s2f CCAATCTCAGCTCACTGCAA 
intron1s2r CTAAGGTGGGAGGATCACGA 
intron1s4f ACCCTGTCAGCGAAAAGAAC 
intron1s4r TTGCCCTTACACCTCTGGTC 
intron1s3f CTTCAGGGTCAGGAAATGGA 
intron1s3r AGGCTGAGGACTGCACAGAT 
Intron 3 PCR Primers cyp17ex3_f1 TGGTACAGAGAGGGGGTAAG 
cyp17ex4_r1 TGTGCCAGGTTCTCTGCTTG 
Sequencing Primers Intron3s1f TGGTTGAAGGTGAGATGCTG 
Intron3s2f AAGCATTCTATACGCATTCATCG 
Intron3s1r AAGCTCCTTAACCCCGCTAA 
cyp17ex3_f1 TGGTACAGAGAGGGGGTAAG 
Intron3s2r GACCTTCAGCCAGAATGGAA 
Intron 4 PCR Primers Intron4F1 AAGCAGAGAACCTGGCACAT 
Intron4R1 TCACTCCGGAATTTCTCCTG 
Sequencing Primers Intron4F1 AAGCAGAGAACCTGGCACAT 
Intron4R1 TCACTCCGGAATTTCTCCTG 
Intron4s1r CTTGCCTGGCCTAGTTTTTG 
Intron4s1f CAGCTATTTGGGAGGCTGAG 
Intron 6 PCR Primers cyp17ex6_f1 ACACACTAGTCACCTCCAAC 
cyp17ex7+8_r1 GCCACATAGGGTGGACAGG 
Sequencing Primers Intron6s1f GCTGGCCAACCTAAAGTCAG 
Intron6s1r ATCTTGGCTCACTGCAACCT 
Intron6s2r GGAAGCTCCTCTGGGAAGTC 
intron6s3r GGGACTTCGTACTCCCTTCC 
Intron 7 PCR Primers cyp17ex7+8_f1 TTCCTCTTCCACTCTGGAGC 
cyp17ex8utr_r1 GAATGAGTGAGCAAATGAATAC 
Sequencing Primers cyp17ex8_r1 TGTGTTGTGGGGCCACATAG 
cyp17ex7+8_r1 GCCACATAGGGTGGACAGG 
intron7s1r GCCCTTAACGACACAGAGGA 
Intron7s2r CAGGCCATGATGAGGAAGAG 
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Table S4: Primers used for site-directed mutagenesis of pGL3-17 Control 
reporter construct. 
 
SNP  Primer  Sequence 5’-3’ 
Base 
Change 
rs2150927 
Sense ATGGGAAATGGTCAAAGGACACCTTCTGGGTAGGG 
T → C 
Antisense CCCTACCCAGAAGGTGTCCTTTGACCATTTCCCAT 
    
rs138009835 
Sense AAGGGAGAGATGTTGTGGGAAGTCAGGGACC 
C → T 
Antisense GGTCCCTGACTTCCCACAACATCTCTCCCTT 
    
rs10786714 
Sense GAGAGAGGCTATAAATGGAGATGCAAGTAGGGAAGATAT 
C → G 
Antisense ATATCTTCCCTACTTGCATCTCCATTTATAGCCTCTCTC 
    
rs10786713 
Sense TGTTTAAGGTGTTTATCAAGACAGTACGTGCACCGCTGAAC 
T → C 
Antisense GTTCAGCGGTGCACGTACTGTCTTGATAAACACCTTAAACA 
    
rs10883784 
Sense GTCTCTCTTTATTTCTCAGCCAGCTGACACTTATAGAAAGAAC 
G → A 
Antisense GTTCTTTCTATAAGTGTCAGCTGGCTGAGAAATAAAGAGAGAC 
    
rs2486758 
Sense CCAGTGATTTTGATTTTGCAGCATGGAAAGTTCCAAGCCTT 
A → G 
Antisense AAGGCTTGGAACTTTCCATGCTGCAAAATCAAAATCACTGG 
    
rs743572 
Sense CAGCTCTTCTACTCCACTGCTGTCTATCTTGCCTG 
C → T 
Antisense CAGGCAAGATAGACAGCAGTGGAGTAGAAGAGCTG 
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Table S5: Primers used to amplify and sequence 2.4kb CYP17A1 upstream 
region in hypertensive BRIGHT subjects. 
 
Primer Type Primer Name Sequence 5’-3’ 
PCR Primers cyp17promF2 ATGCAGTTCGATTGCAACAC 
cyp17promR2 TTGGGCCAAAACAAATAAGC 
Sequencing Primers cyp17promF2 ATGCAGTTCGATTGCAACAC 
cyp17promR2 TTGGGCCAAAACAAATAAGC 
cyp17-1935F AGCTGAGGCGTTAGATCAGG 
cyp17-1525F GTCACTTCAGGACCACTGTGA 
cyp17-1213F CCGCTCTGGGAATGTCTATC 
cyp17-884F TTGTCCTTTCCCTCAGAAGC 
cyp17-603F GAAATATTGGGGGTGGGTTC 
cyp17-159F CCCAGATACCATTCGCACTC 
cyp17-1697R GACTTCCCGCAACATCTCTC 
cyp17-1388R TGGTTGTTTTCCCTTGTTCC 
cyp17-1021R CAGCGGTGCACATACTGTCT 
cyp17-720R TACCCACCTGAGCCTCAAAC 
cyp17-374R TAAGGGCTGTGGGTTAATGG 
cyp17-117R CTCCCCATGCTTGAATGACT 
cyp17+67R GGCTACCCTGATCTTCACCTT 
cyp17-112R GTCAGTTGATCACCCTCTGA 
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Table S6: BRIGHT study subgroup demographics data stratified by SNP 
genotype. 
Demographic data (median and interquartile ranges) of the BRIGHT study subgroup stratified by the 7 
SNP genotypes. Demographic characteristics were compared by the non-parametric Mann-Whitney 
test using the dominant model. SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: 
body mass index; WHR: waist-hip ratio. 
 
 
 
 
 
 
Table S6 continued over 
  
rs743572 
AA 
N=72 
AG 
N=109 
GG 
N=37 
p-value 
(AA vs. AG+GG) 
Age (Years) 63 (58-67) 62 (55-70) 64 (58-68) 0.99 
SBP (mm/Hg) 157 (153-187) 183 (153-190) 155 (152-191) 0.53 
DBP (mm/Hg) 102 (98-107) 103 (99-110) 103 (98-110) 0.51 
BMI (kg/m2) 27 (24-30) 27.5 (25-30) 27 (25-31) 0.47 
WHR 0.86 (0.83-0.92) 0.88 (0.81-0.93) 0.91 (0.83-0.94) 0.49 
rs2486758 
TT 
N=145 
TC 
N=66 
CC 
N=7 
p-value 
TT vs. TC+CC 
Age (Years) 63 (56-67.25) 63 (56-70) 63 (60.5-65) 0.52 
SBP (mm/Hg) 157 (153-190) 181.5 (152-190) 186 (169-189.5) 0.42 
DBP (mm/Hg) 103 (99-108) 103 (98-110.75) 99 (98-103) 0.94 
BMI (kg/m2) 27 (24-30) 27 (25-29) 30 (27-30) 0.81 
WHR 0.89 (0.81-0.93) 0.89 (0.81-0.93) 0.79 (0.76-0.85) 0.44 
rs10883784 
CC 
N=107 
CT 
N=99 
TT 
N=19 
p-value 
CC vs. CT+TT 
Age (Years) 63.5 (58.25-68) 62 (54.5-70) 63 (60.5-67) 0.43 
SBP (mm/Hg) 157 (153-190) 157 (153-190) 153 (152-186.5) 0.76 
DBP (mm/Hg) 103 (98-108) 103 (98-110) 102 (98-110) 0.97 
BMI (kg/m2) 27 (24-30) 27 (25-30) 28 (26-31) 0.38 
WHR 0.86 (0.80-0.92) 0.88 (0.81-0.93) 0.92 (0.89-0.94) 0.30 
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Table S6 (continued) 
rs10786713 
AA 
N=75 
AG 
N=111 
GG 
N=38 
p-value 
AA vs. AG+GG 
Age (Years) 63 (58-67) 63 (55-70) 64.5 (58.5-68) 0.94 
SBP (mm/Hg) 157 (153-187) 183 (153-190) 156 (152-191) 0.76 
DBP (mm/Hg) 102 (98-107) 103 (99-110) 103 (98.25-109) 0.58 
BMI (kg/m2) 27 (24-29.75) 28 (25-30) 27 (24.25-30.75) 0.36 
WHR 0.86 (0.81-0.91) 0.88 (0.81-0.93) 0.91 (0.82-0.94) 0.34 
 
rs10786714 
GG 
N=107 
GC 
N=98 
CC 
N=19 
p-value 
GG vs. GC+CC 
Age (Years) 63.5 (58.25-68) 62.5 (55-70) 63 (60.5-67) 0.49 
SBP (mm/Hg) 157 (153-190) 169 (153-190) 153 (152-186.5) 0.81 
DBP (mm/Hg) 103 (98-108) 103 (98-110) 102(98-110) 0.98 
BMI (kg/m2) 27 (24-30) 27 (25-30) 28 (26-31) 0.39 
WHR 0.86 (0.80-0.92) 0.88 (0.81-0.93) 0.92 (0.89-0.94) 0.26 
 
rs138009835 
GG 
N=178 
GA 
N=45 
AA 
N=2 
p-value 
GG vs. GA+AA 
Age (Years) 63 (56-68) 65 (58-70) 67 (66-68) 0.29 
SBP (mm/Hg) 157 (153-190) 183 (153-197) 156 (155.5-156.5) 0.61 
DBP (mm/Hg) 102.5 (98-110) 103 (100-110) 106 (103-109) 0.72 
BMI (kg/m2) 27 (25-30) 27 (24-30) 25.5 (25-26) 0.51 
WHR 0.88 (0.81-0.93) 0.87 (0.79-0.92) 0.99 (0.96-1.01) 0.66 
 
rs2150927 GG 
N=76 
GA 
N=110 
AA 
N=37 
p-value 
GG vs. GA+AA 
Age (Years) 63 (58-67) 63 (55-70) 64 (58-68) 0.94 
SBP (mm/Hg) 157 (153-187) 182 (153-190) 155 (152-191) 0.90 
DBP (mm/Hg) 102.5 (98-107) 103 (99-110) 103 (98-110) 0.64 
BMI (kg/m2) 27 (24-30) 28 (25-30) 27 (25-31) 0.42 
WHR 0.86 (0.81-0.91) 0.88 (0.80-0.93) 0.91 (0.83-0.94) 0.30 
 
